Spyre Therapeutics (FRA:3920) Ending Cash Position: €140.62 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3920 Spyre Therapeutics Inc FRA:3920
20 GF Score
Price €77.00
GF Value €1.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Spyre Therapeutics Ending Cash Position?

Spyre Therapeutics FRA:3920 +1.32% 20 Ending Cash Position is €140.62 Mil as of Jun. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 20/100 and a GF Value™ of €1.98 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Spyre Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was €140.62 Mil.

Spyre Therapeutics's quarterly Ending Cash Position increased from Dec. 2025 (€73.21 Mil) to Mar. 2026 (€84.07 Mil) and increased from Mar. 2026 (€84.07 Mil) to Jun. 2026 (€140.62 Mil).

Spyre Therapeutics's annual Ending Cash Position declined from Dec. 2023 (€173.51 Mil) to Dec. 2024 (€85.40 Mil) and declined from Dec. 2024 (€85.40 Mil) to Dec. 2025 (€73.21 Mil).

Spyre Therapeutics Ending Cash Position Related Terms

Spyre Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics Ending Cash Position Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.03 34.38 173.51 85.40 73.21

Spyre Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.80 55.29 73.21 84.07 140.62
FRA:3920
20GF Score
Spyre Therapeutics Inc FRA:3920
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Spyre Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=76.368+-3.162
=73.21

Spyre Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=84.357+56.265
=140.62

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €140.62 Mil mean?
Spyre Therapeutics (FRA:3920) has a Ending Cash Position of €140.62 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' Ending Cash Position too high?
Spyre Therapeutics' current Ending Cash Position is €140.62 Mil. Overall, Spyre Therapeutics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Ending Cash Position compare to TGTX and IMVT?
Spyre Therapeutics' Ending Cash Position of €140.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current Ending Cash Position is €140.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spyre Therapeutics (FRA:3920) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.98, compared to a current price of €77.00 — trading 3788.9% above its estimated fair value. The current Ending Cash Position is €140.62 Mil. Spyre Therapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Ending Cash Position is €140.62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?

Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued. The current stock price of €77.00 is trading 3788.9% above its estimated GF Value™ of €1.98. GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:3920:

  • Ending Cash Position: €140.62 Mil
  • GF Value™: €1.98 vs. price of €77.00 (3788.9% above fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
20GF Score

Get the complete analysis for FRA:3920

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price
€1.98
GF Value